share_log

三葉草生物-B：截至2024年4月30日止月份股份發行人的證券變動月報表

CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended April 30, 2024

Hong Kong Stock Exchange ·  May 6 02:36
Summary by Moomoo AI
三葉草生物製藥有限公司（「三叶草生物-B」）於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額為200,000美元，本月無增減變動。然而，在已發行股份變動詳情方面，公司根據股份期權計劃，於本月內有52,000股新股份因行使股份期權而發行，並因此收取了416港元的資金。該股份期權計劃分為首次公開發售前後兩個計劃，分別於2021年4月15日和9月26日獲股東大會通過。本月內，首次公開發售前購股權計劃下有52,000股份期權被行使，而首次公開發售後購股權計劃則有6,993,573股份期權失效。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
三葉草生物製藥有限公司（「三叶草生物-B」）於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的股份變動情況。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額為200,000美元，本月無增減變動。然而，在已發行股份變動詳情方面，公司根據股份期權計劃，於本月內有52,000股新股份因行使股份期權而發行，並因此收取了416港元的資金。該股份期權計劃分為首次公開發售前後兩個計劃，分別於2021年4月15日和9月26日獲股東大會通過。本月內，首次公開發售前購股權計劃下有52,000股份期權被行使，而首次公開發售後購股權計劃則有6,993,573股份期權失效。公司確認所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Clover Biopharmaceuticals Limited (“Shamus Bio-B”) filed with Hong Kong Trading and Clearing Limited on 6 May 2024 an updated Monthly Statement of Changes in Securities Reporting for the year ended 30 April 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease this month. However, in terms of the details of the changes in the issued shares, the company issued 52,000 new shares under the share option scheme during the month as a result of the exercise of the share options and as a result received HK$416. The share option plan is divided into two plans before and after the initial public offering...Show More
Clover Biopharmaceuticals Limited (“Shamus Bio-B”) filed with Hong Kong Trading and Clearing Limited on 6 May 2024 an updated Monthly Statement of Changes in Securities Reporting for the year ended 30 April 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease this month. However, in terms of the details of the changes in the issued shares, the company issued 52,000 new shares under the share option scheme during the month as a result of the exercise of the share options and as a result received HK$416. The share option plan is divided into two plans before and after the initial public offering, which were approved by the General Meeting on April 15 and September 26, 2021, respectively. During this month, 52,000 share options were exercised under the Initial Public Offering pre-IPO share option plan, and 6,993,573 share options expired under the Initial Public Offering post-IPO share option plan. The Company confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more